Moreover, SAgs were fused with the third loop of transforming growth factor α (TGFαL3) to study the possibility of the therapeutic application of TGFαL3-SAg as a novel anti-tumor candidate in EGFR tumor-expressing cells [37,42,43,44]. Here, EGFR is linked to neoplasm.